Regenxbio adds to metabolics franchise with acquisition

30 August 2017
mergers-acquisitions-big

US biotech Regenxbio (Nasdaq: RGNX) has entered a definitive deal to acquire Dimension Therapeutics (Nasdaq: DMTX) in an all-stock transaction for an implied value of about $3.41 per share.

This values the transaction at around $86 million, and the offer price is nearly three times that of Dimension’s closing price of $1.20 ahead of the announcement, which caused the company’s shares to skyrocket 160% as an instant reaction. The boards of directors of both companies have unanimously approved the transaction.

On completion of the acquisition, Regenxbio will add two lead product candidates to its pipeline:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology